{"nctId":"NCT03057431","briefTitle":"Hydrochlorothiazide for Kidney Stone Recurrence Prevention","startDateStruct":{"date":"2017-03-09","type":"ACTUAL"},"conditions":["Nephrolithiasis"],"count":416,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo oral capsule"]},{"label":"12.5 mg hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: 12.5 mg hydrochlorothiazide"]},{"label":"25.0 mg hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: 25.0 mg hydrochlorothiazide"]},{"label":"50.0 mg hydrochlorothiazide","type":"EXPERIMENTAL","interventionNames":["Drug: 50.0 mg hydrochlorothiazide"]}],"interventions":[{"name":"Placebo oral capsule","otherNames":[]},{"name":"12.5 mg hydrochlorothiazide","otherNames":[]},{"name":"25.0 mg hydrochlorothiazide","otherNames":[]},{"name":"50.0 mg hydrochlorothiazide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age 18 years or older\n3. Recurrent kidney stone disease (â‰¥ 2 stone events within the last 10 years prior to randomization)\n4. Any past kidney stone containing 50% or more of calcium oxalate, calcium phosphate or a mixture of both\n\nExclusion Criteria:\n\n1. Pharmacologic prevention for stone recurrence less than 3 months prior to randomization\n2. Patients with secondary causes of recurrent calcareous nephrolithiasis including:\n\n   * Severe eating disorders (anorexia or bulimia)\n   * Chronic inflammatory bowel disease, bariatric surgery, intestinal surgery with malabsorption or chronic diarrheal status\n   * Sarcoidosis\n   * Primary hyperparathyroidism\n   * Complete distal tubular acidosis\n   * Active malignancy\n3. Patients with the following medications:\n\n   * Thiazide or loop diuretics\n   * Carbonic anhydrase inhibitors (including topiramate)\n   * Xanthine oxidase inhibitors (febuxostat or allopurinol)\n   * Alkali, including potassium citrate or sodium bicarbonate\n   * Treatment with 1,25-OH Vitamin D (calcitriol)\n   * Calcium supplementation\n   * Bisphosphonates\n   * Denosumab\n   * Teriparatide\n   * Glucocorticoids\n4. Obstructive uropathy, if not treated successfully\n5. Urinary tract infection, if not treated successfully\n6. Chronic kidney disease (defined as CKD-EPI eGFR \\< 30 mL/min per 1,73 m2 body surface area for more than 3 months)\n7. Patients with a kidney transplant\n8. \\> 3 gout arthritis episodes within one year prior to randomisation or gout arthritis requiring uric acid lowering therapy\n9. Cystinuria at screening\n10. Hypokalemia (blood potassium level \\< 3 mmol/L) at screening\n11. Hyponatremia (blood sodium level \\< 125 mmol/L) at screening\n12. Pregnant and lactating women \\[pregnancy test to be performed for women of child-bearing potential (defined as women who are not surgically sterilized/ hysterectomized, and/ or who are postmenopausal for less than 12 months)\\]\n13. Previous (within 3 months prior to randomization) or concomitant participation in another interventional clinical trial\n14. Inability to understand and follow the protocol\n15. Known allergy to the study drug","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Stone Recurrences","description":"Composite of symptomatic or radiological recurrences, defined as either a symptomatic kidney stone passage or radiological kidney stone recurrence on CT.\n\nSymptomatic recurrence was defined as the visible passage of a stone with or without accompanying typical symptoms (such as flank or loin pain and hematuria) or as the presence of a symptomatic or asymptomatic stone that was determined to require surgical removal. If a patient had symptoms during the trial that were suggestive of a possible stone passage but no visible stone had been observed, local investigators evaluated the symptoms of the patient and judged whether a stone passage had occurred. Radiological recurrence was defined as a new stone formed or enlargement of a preexisting stone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"61","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Symptomatic Stone Recurrences","description":"Symptomatic recurrence was defined as the visible passage of a stone with or without accompanying typical symptoms (such as flank or loin pain and hematuria) or as the presence of a symptomatic or asymptomatic stone that was determined to require surgical removal. If a patient had symptoms during the trial that were suggestive of a possible stone passage but no visible stone had been observed, local investigators evaluated the symptoms of the patient and judged whether a stone passage had occurred.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"43","spread":null},{"groupId":"OG003","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Radiologic Stone Recurrences.","description":"Radiological stone recurrence was defined as a new stone formed or enlargement of a preexisting stone (assessed by low-dose CT of the kidney at the end of the study compared to the low-dose CT of the kidney at the baseline visit).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":102},"commonTop":["New onset diabetes mellitus"]}}}